Neiromidin (Ipidacrine Hydrochloride)

Ipidacrine Hydrochloride, the active ingredient in Neiromidin, is an acetylcholinesterase inhibitor presented as an oral tablet for systemic administration. By inhibiting acetylcholinesterase, it increases acetylcholine levels, supporting neuromuscular transmission and cognitive function in relevant disorders.

GNH USA supplies Neiromidin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with the product sourced from EU‑regulated manufacturers and meeting stringent quality standards. The company provides reliable logistics and regulatory support for cross‑border shipments and timely delivery, ensuring patient access.

Neiromidin (Ipidacrine Hydrochloride) acts as an acetylcholinesterase inhibitor and is used in neuromuscular and cognitive disorders.

- Myasthenia gravis: improves muscle strength by enhancing neuromuscular transmission. - Dementia (including Alzheimer’s disease): may modestly improve cognitive symptoms through increased central acetylcholine. - Post‑stroke cognitive impairment: supports recovery of attention and memory functions.

Neiromidin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Bradycardia: markedly reduced heart rate requiring medical attention. - Severe cholinergic crisis: muscle weakness, respiratory difficulty, and excessive salivation. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

When prescribing Neiromidin, clinicians should consider several precautionary measures to ensure safe use. - Assess neuromuscular status: evaluate for myasthenic symptoms before initiating therapy. - Monitor cardiac function: watch for bradycardia, especially in patients with pre‑existing conduction disorders. - Review concomitant cholinergic drugs: avoid additive cholinergic effects. - Caution in hepatic impairment: dose adjustment may be required due to hepatic metabolism. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Neiromidin can interact with other medications that influence cholinergic activity or cardiac conduction.

Major Interactions (Avoid): - Anticholinergic agents (e.g., atropine, scopolamine): may counteract therapeutic effect. - Beta‑blockers and calcium channel blockers: increased risk of bradycardia. - Other acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine): risk of cholinergic overload.

Moderate Interactions (Monitor Closely): - QT‑prolonging drugs (e.g., quinidine, macrolide antibiotics): may exacerbate cardiac conduction effects. - Diuretics: potential electrolyte disturbances affecting cardiac rhythm. - CNS depressants (e.g., benzodiazepines): may enhance dizziness or fatigue.